A life course approach to cardiovascular disease prevention

Journal of Cardiovascular Nursing

Volumn 26, Issue 4 SUPPL., 2011, Pages

  Hayman, Laura L ^a,b   Helden, Liz ^c   Chyun, Deborah A ^d   Braun, Lynne T ^e  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b GoKids Boston   (United States)

^c MCMASTER CHILDREN S HOSPITAL   (Canada)

^d NEW YORK UNIVERSITY   (United States)

^e RUSH UNIVERSITY COLLEGE OF NURSING   (United States)

Author keywords

CVD; life course; prevention

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; HEALTH; HEALTH BEHAVIOR; HEALTH EDUCATION; HUMAN; INTERDISCIPLINARY COMMUNICATION; LIFESTYLE; NURSE ATTITUDE; NURSING; NURSING DISCIPLINE; NURSING PRACTICE; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PRIMARY PREVENTION; RISK REDUCTION;

CARDIOVASCULAR DISEASES; HEALTH BEHAVIOR; HEALTH EDUCATION; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIFE STYLE; NURSE'S PRACTICE PATTERNS; NURSE'S ROLE; PATIENT EDUCATION AS TOPIC; PRIMARY PREVENTION; RISK REDUCTION BEHAVIOR; SPECIALTIES, NURSING; WORLD HEALTH;

EID: 79958791158     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0b013e318213ef7f     Document Type: Article

References (79)

1. Halfon N, Holstein M. Life course health development: an integrated framework for developing health, policy and research. Milbank Q. 2002;80(3):433-479.
2. Ben-Shlomo Y, Kuh D. A life course approach to chronic disease epidemiology: conceptual models, empirical challenges and interdisciplinary perspectives. Int J Epidemiol. 2002;31(2):285-293. (Pubitemid 34537777)
3. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107(4):1562- 1566. (Pubitemid 36378499)
4. Daniels SR, Greer FR; and the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198-208.
5. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation. 2009;119:1161-1175.
6. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650-1656. (Pubitemid 28267909)
7. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1995; 15(9):512-1531.
8. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP; and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15:431-440.
9. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-media thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001;104:2815-2819. (Pubitemid 33126656)
10. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290(17): 2271-2276. (Pubitemid 37430559)
11. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290(17):2277-2283. (Pubitemid 37430560)
12. Urbina EM, Kimball TR, McCoy CE, Khoury PR, Daniels SR, Dolan LM. Youth with obesity and obesity-related type 2 diabetes mellitus demonstrate abnormalities in carotid structure and function. Circulation. 2009;119(22):2913-2919.
13. Lauer RM, Clarke WR. Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia: the Muscatine Study. JAMA. 1990;264(23):3034-3038.
14. Webber LS, Srinivasan SR, Wattigney WA, Berenson GS. Tracking of serum lipids and lipoproteins from childhood to adulthood; the Bogalusa Heart Study. Am J Epidemiol. 1991;133(9):884-899.
15. Riddoch C, Edwards D, Page A, et al. The European Youth Heart Study. Cardiovascular disease risk factors in children: rationale, aims, design, and validation of methods. J Phys Act Health. 2005;2:115-129.
16. Porkka KV, Viikari JS, Taimela S, Dahl M, Akerblom HK. Tracking and predictiveness of serum lipid and lipopro-teins measurements in childhood: a 12-year follow-up: the Cardiovascular Risk in Young Finns study. Am J Epidemiol. 1994;140(12):1096-1110.
17. Lee DS, Chiu M, Manuel DG, et al; Canadian Cardiovascular Outcomes Research Team. Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors. CMAJ. 2009;181(3-4):E55-E66.
18. Paradis G, Lambert M, O'Loughlin J, et al. The Quebec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth. Can J Cardiol. 2003;19(5):523-531. (Pubitemid 36705618)
19. Janssen I, Katzmarzyk PT, Boyce WF, et al; Health Behavior in School-Aged Children Obesity Working Group. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationships with physical activity and dietary patterns. The International Association for the Study of Obesity. Obes Rev. 2005;6(2):123-132. (Pubitemid 40604421)
20. Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV. Co-existence of severe insulin resistance and hyperinsulinae-mia in pre-adolescent obese children. Diabetologia. 1996; 39(12):1489-1497. (Pubitemid 26397355)
21. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5):664-672. (Pubitemid 30318399)
22. Gidding SS. Dyslipidemia in the metabolic syndrome in children. J Cardiometab Syndr. 2006;1(4):282-285.
23. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA. 2007;298(8): 874-879. (Pubitemid 47311293)
24. Steinberger J, Daniels SR, Eckel R, et al. Progress and challenges in the metabolic syndrome in children and adolescents. Circulation. 2009:119(4);628-647.
25. Lau D, Douketis J, Morrison KM, Hramiak I, Sharma A, Ur E. Expert panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children: summary report. CMAJ. 2007;176(suppl 8): S1-S13.
26. Barlow SE; for the Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent, overweight and obesity: summary report. Pediatrics. 2007;20(suppl 4):S164-S192.
27. Morrison KM, Atkinson SA, Yusuf S, et al; FAMILY Investigators. The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis. Am Heart J. 2009;158(4):533-539.
28. Olsen J, Melbye M, Olsen SF, et al. The Danish national birth cohortVits background, structure and aim. Scand J Public Health. 2001;29(4):300-307. (Pubitemid 33731020)
29. Reilly JJ, Armstrong J, Dorosty AR, et al. Early life risk factors for obesity in childhood: cohort study. BMJ. 2005; 330(7504):1357-1364.
30. National Institutes of Health. National Heart, Lung, and Blood Institute. NHLBI Pediatric Guidelines for Cardiovascular Health Promotion and Risk Reduction. 2010. In press.
31. A Race Against Time. The Challenge of Cardiovascular Disease in Developing Economies. http://www.earth.columbia. edu/news/2004/images/ raceagainsttime-FINAL-051104.pdf. Accessed June 18, 2010.
32. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18): 1837-1847. (Pubitemid 28213628)
33. Greenberg H, Raymond SU, Leeder SR. Cardiovascular disease and global health: threat and opportunity. Health Affairs Web Exclusive. 2005;W5-31-W5-41. http://content.healthaffairs.org.ezproxy.lib.umb.edu/cgi/reprint/hlthaff.w5. 31v1. Accessed June 20, 2010.
34. Reddy KS. India wakes up to the threat of cardiovascular diseases. J Am Coll Cardiol. 2007;50(14):1370-1372. (Pubitemid 47446090)
35. American Heart Association. Heart disease and stroke statistics: 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21-e181.
36. Grundy SM, Cleeman JI, Merz CNB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110(2):227-239. (Pubitemid 38924592)
37. Nakamura H, Arakawa K, Itakura H, et al; for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet. 2006;368(9540): 1155-1163 (Pubitemid 44444932)
38. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000; 356(9246):1955-1964.
39. United Nations. World Population Prospects: The 2002 Revision (Medium Scenario). New York, NY: United Nations Publication 2003.
40. United Nations. World Population Prospects: The 2004 Revision. United Nations Publication; 2005.
41. United Nations. Population Challenges and Development Goals. United Nations Publication; 2005. Sales No. E.05.XIII.8.
42. Department of Economic and Social Affairs. UN Secretariat. The Diversity of Changing Population Age Structures in the World. New York, NY: Department of Economic and Social Affairs Population Division; 2005.
43. Population Reference Bureau Staff. Popul Bull. 2004;59
44. Asia Pacific Cohort Studies Collaboration. The impact of cardiovascular risk factors on the age-related excess of coronary heart disease. Int J Epidemiol. 2006;35(4):1025-1033.
45. Martiniuk AL, Lee CM, Lawes CM, et al; for the Asia-Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens. 2007;25(1):73-79. (Pubitemid 44885666)
46. Sasayama S. Heart disease in Asia. Circulation. 2008;118: 2669-2671.
47. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359. (Pubitemid 34251969)
48. Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. N Engl J Med. 1998;338(15): 1035-1041. (Pubitemid 28180406)
49. Gill TM, Baker DI, Gottschalk M, Gahabuer EA, Charpentier PA, de Regt PT. A rehabilitation program for physically frail community-living older persons. Arch Phys Med Rehabil. 2003;84(3):394-404. (Pubitemid 36297739)
50. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728-1735.
51. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol lowering therapy in women and elderly patients with myo-cardial infarction or angina pectoris: findings from the 4S study. Circulation. 1997;96(12):4211-4218. (Pubitemid 28007446)
52. LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340-2346. (Pubitemid 30013066)
53. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events Trial (CARE). Ann Intern Med. 1998;129(9):681-689. (Pubitemid 28507140)
54. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357
55. Diabetes Prevention Program Research Group. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
56. Yusuf S, Hawken S, Gunpuu S, et al; and the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438):937-952 (Pubitemid 39208455)
57. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005; 112(22):3384-3390.
58. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham Risk Score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ. 2008;337:a3083. doi:10.1136/bmj.a3083.
59. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients Q75 years of age). Circulation. 2002;105(14): 1735-1743.
60. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346): 1623-1630. (Pubitemid 35379733)
61. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898. (Pubitemid 351620109)
62. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388-391. (Pubitemid 34778969)
63. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, the Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(suppl V):v1-v52.
64. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status and future directions. Circulation. 2010;121:1768-1777.
65. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25): 3143-3421.
66. D'Agostino RB, Grundy SM, Sullivan LM, Wilson P; for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-187. (Pubitemid 32640849)
67. Brindle P, May M, Gill P, et al. Primary prevention of cardiovascular disease: a Web-based risk score for seven British black and minority ethnic groups. Heart. 2006; 92(11):1595-1602. (Pubitemid 44629163)
68. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008;117(6):743-753. (Pubitemid 351640675)
69. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-315. (Pubitemid 34106178)
70. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK a new cardiovascular risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136.
71. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297:611-619.
72. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global risk prediction: the Reynolds score for men. Circulation. 2008;118:2243-2251.
73. New Zealand Guidelines Group. New Zealand Cardiovascular Guidelines Handbook: A Summary Resource for Primary Care Practitioners. 2nd ed. Wellington, New Zealand: New Zealand Guidelines Group, 2009.
74. Conroy RM, Pyorala K, Fitzgerald AP, et al; SCORE Project Group. Estimation of ten year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11):987-1003. (Pubitemid 36712275)
75. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham Risk Score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20-24. (Pubitemid 38813447)
76. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999; 353(9147):89-92. (Pubitemid 29088076)
77. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791-798.
78. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113(19):2363-2372. (Pubitemid 43947981)
79. Mosca L, Benjamin E, Berra K, et al. Evidence-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. [published online ahead of print February 16, 2011] Circulation. 2011;123:1243-1262